Lymphoma

NEW ORLEANS — Since war started in Ukraine, tertiary care centers focused on treating cancers saw a 56% decline in patients with lymphoma, a presenter said.

The FDA approved zanubrutinib for treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma.

NEW ORLEANS — Looking at 185 countries, a projection presented at the ASH Annual Meeting and Exhibition suggests the global burden of non-Hodgkin lymphoma will increase by 778,000 cases by 2040.

NEW ORLEANS — Patients diagnosed with lymphoma were likely to experience anxiety and depression, lowering overall quality of life, according to a presenter at ASH Annual Meeting and Exhibition.

NEW ORLEANS — Induction with brentuximab vedotin plus AVD chemotherapy followed by nivolumab consolidation exhibited encouraging activity among previously untreated patients with limited-stage non-bulky Hodgkin lymphoma, according to study results.

NEW ORLEANS — Lisocabtagene maraleucel can be administered safely in the community setting to patients relapsed or refractory large B-cell lymphoma, according to phase 2 study results.

NEW ORLEANS — A novel chimeric antigen receptor T-cell therapy showed encouraging early efficacy among heavily pretreated patients with CD19-positive non-Hodgkin lymphoma, according to study results.

NEW ORLEANS — Bendamustine lymphodepletion resulted in significant CAR T-cell expansion among patients with relapsed or refractory non-Hodgkin lymphoma, according to study results presented at ASH Annual Meeting and Exposition.

NEW ORLEANS — Consolidation therapy with high-dose chemotherapy followed by hematopoietic stem cell transplant significantly prolonged PFS among adults with primary central nervous system lymphoma, according to study results.

The addition of brentuximab vedotin and nivolumab to doxorubicin and dacarbazine appeared promising for adults with bulky stage II or stage III/stage IV classic Hodgkin lymphoma, according to study results.